<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Ascentage Pharma Group International — News on 6ix</title>
    <link>https://6ix.com/company/ascentage-pharma-grp-international</link>
    <description>Latest news and press releases for Ascentage Pharma Group International on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 22 Apr 2026 00:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/ascentage-pharma-grp-international" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68368cdc78dffbe2df16d14e.webp</url>
      <title>Ascentage Pharma Group International</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international</link>
    </image>
    <item>
      <title>Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-data-from-multiple-trials-including-three-rapid-oral-presentations-at-asco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-data-from-multiple-trials-including-three-rapid-oral-presentations-at-asco-2026</guid>
      <pubDate>Wed, 22 Apr 2026 00:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, April 21, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, today announced that six abstracts from clinical studies of three key drug candidates have been selected for presentation at the 2026 American Society of Clinical O</description>
    </item>
    <item>
      <title>Ascentage Pharma to Present Four Promising Preclinical Studies Demonstrating the Potential of Combination Therapies at American Association for Cancer Research (AACR) 2026 Annual Meeting</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-four-promising-preclinical-studies-demonstrating-the-potential-of-combination-therapies-at-american-association-for-cancer-research-aacr-2026-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-four-promising-preclinical-studies-demonstrating-the-potential-of-combination-therapies-at-american-association-for-cancer-research-aacr-2026-annual-meeting</guid>
      <pubDate>Mon, 20 Apr 2026 00:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, April 19, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it will present four preclinical studies in poster format at the American Association for Cancer Research (AACR) 2026 Annual Meeting, held April 17 t</description>
    </item>
    <item>
      <title>Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-reports-full-year-2025-unaudited-financial-results-and-provides-business-updates</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-reports-full-year-2025-unaudited-financial-results-and-provides-business-updates</guid>
      <pubDate>Wed, 25 Mar 2026 23:00:00 GMT</pubDate>
      <description>Product sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million)Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor event with simultaneous conference call and web</description>
    </item>
    <item>
      <title>Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-data-from-four-preclinical-studies-in-its-innovative-pipeline-at-american-association-of-cancer-research-aacr-annual-meeting-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-data-from-four-preclinical-studies-in-its-innovative-pipeline-at-american-association-of-cancer-research-aacr-annual-meeting-2026</guid>
      <pubDate>Wed, 18 Mar 2026 00:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Ass</description>
    </item>
    <item>
      <title>Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-report-full-year-2025-unaudited-financial-results-and-provide-business-updates-on-march-25-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-report-full-year-2025-unaudited-financial-results-and-provide-business-updates-on-march-25-2026</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, today reported it will release its full year 2025 unaudited results and provi</description>
    </item>
    <item>
      <title>Ascentage Pharma to Participate in Three Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences</guid>
      <pubDate>Mon, 23 Feb 2026 13:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&apos;s management is scheduled to participate in three upcoming investor conferences. Oppenheimer 3</description>
    </item>
    <item>
      <title>Ascentage Pharma to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-guggenheim-emerging-outlook-biotech-summit-2026</guid>
      <pubDate>Mon, 09 Feb 2026 13:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company, a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company&apos;s management is scheduled to participate in the Guggenheim Emerging Outlook: Biotech Summit 2026</description>
    </item>
    <item>
      <title>Ascentage Pharma Announces IND Clearance by the China CDE for BTK Degrader APG-3288</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-ind-clearance-233000320</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-ind-clearance-233000320</guid>
      <pubDate>Thu, 05 Feb 2026 23:30:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that its novel next-generation Bruton&apos;s tyrosine kinase (BTK)-targeted protein degrader, APG-3288, has received investigational new drug (IND) application</description>
    </item>
    <item>
      <title>Ascentage Pharma Outlined its Global Innovation Strategy During Presentation at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-outlined-global-innovation-012500120</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-outlined-global-innovation-012500120</guid>
      <pubDate>Thu, 15 Jan 2026 01:25:00 GMT</pubDate>
      <description>Two commercialized hematology products, Olverembatinib and Lisaftoclax, drive dual-engine growth with strong China market presenceNext-generation BTK protein degrader APG-3288 receives IND clearance from the U.S. FDA, propelling expansion of global innovative pipelineMultiple global registrational Phase III trials are progressing rapidly ROCKVILLE, Md. and SUZHOU, China, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage,</description>
    </item>
    <item>
      <title>Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-ind-clearance-010000011</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-ind-clearance-010000011</guid>
      <pubDate>Wed, 07 Jan 2026 01:00:00 GMT</pubDate>
      <description>Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug (IND) clearance from the U.S. FDA, marking another major expansion to the company’s global innovative pipeline.Ascentage Pharma will conduct a global Phase I study evaluating APG-3288 in patients with relapsed/refractory B-cell malignancies. ROCKVILLE, Md. and SUZHOU, China, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a</description>
    </item>
    <item>
      <title>Ascentage Pharma to Present at 44th Annual J.P. Morgan Healthcare Conference</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-at-44th-annual-jp-morgan-healthcare-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-present-at-44th-annual-jp-morgan-healthcare-conference</guid>
      <pubDate>Wed, 17 Dec 2025 13:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management plans to present at the 44th Annual J.P. Morgan Healthcare Conference in San Fran</description>
    </item>
    <item>
      <title>ASH 2025 | Ascentage Pharma Presents First Dataset from Phase III POLARIS-1 Study of Olverembatinib in Newly Diagnosed Ph+ ALL Shows a Best MRD-Negativity CR Rate Exceeding 60%</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-first-dataset-from-phase-iii-polaris-1-study-of-olverembatinib-in-newly-diagnosed-ph-all-shows-a-best-mrd-negativity-cr-rate-exceeding-60percent</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-first-dataset-from-phase-iii-polaris-1-study-of-olverembatinib-in-newly-diagnosed-ph-all-shows-a-best-mrd-negativity-cr-rate-exceeding-60percent</guid>
      <pubDate>Tue, 09 Dec 2025 00:45:00 GMT</pubDate>
      <description>By the end of 3 induction cycles, the best minimal residual disease (MRD) negativity rate and the MRD-negative complete response (CR) rate were 66.0% and 64.2%, respectivelyHigh-risk IKZF1plus patients showed 90% molecular response rate Low-intensity chemotherapy combination achieved deep responses with favorable safety profile ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrate</description>
    </item>
    <item>
      <title>ASH 2025 | Updated Data for Ascentage Pharma‘s Olverembatinib in Second-Line CML-CP Showing Encouraging Potential for Early-Line Treatment</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-updated-data-for-ascentage-pharmas-olverembatinib-in-second-line-cml-cp-showing-encouraging-potential-for-early-line-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-updated-data-for-ascentage-pharmas-olverembatinib-in-second-line-cml-cp-showing-encouraging-potential-for-early-line-treatment</guid>
      <pubDate>Tue, 09 Dec 2025 00:45:00 GMT</pubDate>
      <description>76.7% complete cytogenetic response rate achieved in patients who failed second-generation TKI first-line therapy Molecular responses continue to deepen with extended treatment duration, reaching 60% major molecular response at 21 cyclesStrong efficacy data support potential advancement to earlier treatment lines for a broader patient population ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercia</description>
    </item>
    <item>
      <title>ASH 2025 | Ascentage Pharma Presents Four-Year Follow-Up Data from Registrational Phase II Study of Olverembatinib, Reaffirming Differentiated Long-Term Efficacy and Safety in TKI-Resistant/Intolerant CML-CP</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-four-year-follow-up-data-from-registrational-phase-ii-study-of-olverembatinib-reaffirming-differentiated-long-term-efficacy-and-safety-in-tki-resistantintolerant-cml-cp</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-four-year-follow-up-data-from-registrational-phase-ii-study-of-olverembatinib-reaffirming-differentiated-long-term-efficacy-and-safety-in-tki-resistantintolerant-cml-cp</guid>
      <pubDate>Tue, 09 Dec 2025 00:45:00 GMT</pubDate>
      <description>Dramatically improved disease control with 21.2 months vs. 2.9 months median event-free survival (EFS) Favorable safety profile with 7% vascular occlusion rate Broad patient benefit with proven effectiveness even in patients without T315I mutation (11.9 vs. 3.1 months event-free survival) ROCKVILLE, Md. and SUZHOU, China, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in t</description>
    </item>
    <item>
      <title>ASH 2025 | Ascentage Pharma Presents Encouraging Data from Phase Ib/II Study of Bcl-2 Inhibitor Lisaftoclax in Venetoclax–Exposed Patients with Myeloid Malignances</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-encouraging-data-from-phase-ibii-study-of-bcl-2-inhibitor-lisaftoclax-in-venetoclax-exposed-patients-with-myeloid-malignances</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ash-2025-or-ascentage-pharma-presents-encouraging-data-from-phase-ibii-study-of-bcl-2-inhibitor-lisaftoclax-in-venetoclax-exposed-patients-with-myeloid-malignances</guid>
      <pubDate>Mon, 08 Dec 2025 01:10:00 GMT</pubDate>
      <description>Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients80% ORR achieved in newly diagnosed high-risk MDS/CMMLStrong safety profile with no dose-limiting toxicities across all patient cohorts in 103-patient study ROCKVILLE, Md. and SUZHOU, China, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated b</description>
    </item>
    <item>
      <title>Ascentage Pharma Presents Pivotal China Registrational Study Data for Lisaftoclax in Oral Report at 2025 American Society of Hematology (ASH) Annual Meeting</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-presents-pivotal-china-registrational-study-data-for-lisaftoclax-in-oral-report-at-2025-american-society-of-hematology-ash-annual-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-presents-pivotal-china-registrational-study-data-for-lisaftoclax-in-oral-report-at-2025-american-society-of-hematology-ash-annual-meeting</guid>
      <pubDate>Sat, 06 Dec 2025 15:15:00 GMT</pubDate>
      <description>Lisaftoclax monotherapy demonstrated significant and durable clinical efficacy and a manageable safety profile in patients with heavily pretreated BTK-refractory R/R CLL/SLL, underscoring its utility as a potential new treatment option Lisaftoclax achieved a 62.5% objective response rate (ORR) in heavily pretreated, BTKi-refractory patients, nearly half with complex karyotypeLisaftoclax monotherapy demonstrated a median progression-free survival of 23.89 months in patients with heavily pretreate</description>
    </item>
    <item>
      <title>Ascentage Pharma Announces Global Registrational Phase III Study of Olverembatinib in First-Line Treatment of Ph+ ALL Cleared by US FDA and EMA</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-global-registrational-phase-iii-study-of-olverembatinib-in-first-line-treatment-of-ph-all-cleared-by-us-fda-and-ema</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-global-registrational-phase-iii-study-of-olverembatinib-in-first-line-treatment-of-ph-all-cleared-by-us-fda-and-ema</guid>
      <pubDate>Fri, 05 Dec 2025 00:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance from the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct a global registrational Ph</description>
    </item>
    <item>
      <title>Ascentage Pharma to Host Webcast Highlighting Key Data from ASH 2025</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-host-webcast-highlighting-key-data-from-ash-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-host-webcast-highlighting-key-data-from-ash-2025</guid>
      <pubDate>Mon, 01 Dec 2025 13:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that Chairman &amp; CEO, Dr. Dajun Yang, and others from the management team will host an investor webcast to provi</description>
    </item>
    <item>
      <title>Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-publication-of-olverembatinib-phase-ib-safety-efficacy-and-novel-mechanism-data-in-gastrointestinal-stromal-tumors-in-natures-signal-transduction-and-targeted-therapy</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-announces-publication-of-olverembatinib-phase-ib-safety-efficacy-and-novel-mechanism-data-in-gastrointestinal-stromal-tumors-in-natures-signal-transduction-and-targeted-therapy</guid>
      <pubDate>Tue, 25 Nov 2025 00:00:00 GMT</pubDate>
      <description>Largest prospective clinical trial to-date in a rare subtype of GIST ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced the publication of clinical and translational data from a Phase Ib study (NCT0359</description>
    </item>
    <item>
      <title>Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025</title>
      <link>https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-december-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/ascentage-pharma-grp-international/news/ascentage-pharma-to-participate-in-three-upcoming-investor-conferences-in-december-2025</guid>
      <pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
      <description>ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that the Company’s management is scheduled to participate in three upcoming investor conferences in December 20</description>
    </item>
  </channel>
</rss>